Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. SOFIVA GENOMICS Co's Revenue for the
three
months ended in Jun. 2026 was NT$97.1 Mil. SOFIVA GENOMICS Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was NT$52.9 Mil.
Hence, SOFIVA GENOMICS Co's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.83.
SOFIVA GENOMICS Co (ROCO:6615) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
SOFIVA GENOMICS Co Receivables Turnover Related Terms
SOFIVA GENOMICS Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for SOFIVA GENOMICS Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6615 vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOFIVA GENOMICS Co Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where SOFIVA GENOMICS Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOFIVA GENOMICS Co (ROCO:6615) has a Receivables Turnover of 1.83 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on SOFIVA GENOMICS Co and its competitors. According to the industry distribution chart, SOFIVA GENOMICS Co ranks #62 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 30.8%.
Is SOFIVA GENOMICS Co's Receivables Turnover too high?
SOFIVA GENOMICS Co's current Receivables Turnover is 1.83. The Medical Diagnostics & Research industry median Receivables Turnover is 5.39. SOFIVA GENOMICS Co's value of 1.83 is 66% below this industry median. Based on the distribution chart, SOFIVA GENOMICS Co ranks #62 out of 201 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, SOFIVA GENOMICS Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SOFIVA GENOMICS Co ranks #62 out of 201 companies for Receivables Turnover. This puts SOFIVA GENOMICS Co in the upper half of its industry. The industry median Receivables Turnover is 5.39. SOFIVA GENOMICS Co's value of 1.83 is 66% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.39, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SOFIVA GENOMICS Co's current Receivables Turnover of 1.83 is 66% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on SOFIVA GENOMICS Co and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOFIVA GENOMICS Co's current Receivables Turnover is 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.73, compared to a current price of NT$34.45 — trading 8.6% above its estimated fair value. The current Receivables Turnover is 1.83 and 66% below the Medical Diagnostics & Research industry median of 5.39. SOFIVA GENOMICS Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current Receivables Turnover is 1.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued.
The current stock price of NT$34.45 is trading 8.6% above its estimated GF Value™ of NT$31.73.
GuruFocus considers SOFIVA GENOMICS Co to be Fairly Valued.
Key valuation signals for ROCO:6615:
Receivables Turnover: 1.83
GF Value™: NT$31.73 vs. price of NT$34.45 (8.6% above fair value)
Industry Position: 66% below the Medical Diagnostics & Research median (#62 of 201)
No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
68GF Score
Get the complete analysis for ROCO:6615
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6615 has been successfully added to your 
